Chemotherapy in Turkey

Most nationalities can obtain a Turkish e-visa online before travel, which permits a stay of up to ninety days within any one-hundred-and-eighty-day period. Turkey does not have a dedicated medical visa category, so the standard tourist or e-visa applies to most medical tourists. Patients should check current visa requirements for their specific nationality.

Turkey uses the Turkish Lira (TRY). Major private hospitals and internationally oriented clinics typically accept payment in euros, US dollars, or pounds sterling in addition to Lira, which is useful for patients who have budgeted in their home currency. Currency exchange facilities are widely available.

English is spoken well at JCI-accredited hospitals and the larger internationally oriented private clinics in Istanbul, where dedicated international patient coordinators handle communication. In smaller clinics and hair transplant centres, English proficiency varies and patients should confirm language support arrangements before booking.

Check whether the facility holds Ministry of Health health tourism certification or JCI accreditation, both of which indicate baseline quality standards. Independently verify the surgeon's medical licence through the Turkish Medical Association, and be cautious of clinics that communicate primarily through social media, offer unusually low prices, or cannot provide verifiable before-and-after outcomes data.

Patients can file complaints with the Turkish Ministry of Health or Turkish Medical Association. Civil litigation is available but pursuing a case from abroad is practically and financially challenging. The 2014 mandatory malpractice insurance law means physicians should carry insurance, but claim resolution can be slow. Choosing a reputable, accredited facility substantially reduces the likelihood of adverse outcomes.

Flying timelines depend on the procedure performed. For hair transplants, most patients fly home within three to five days. For surgical procedures, patients should remain for the post-operative review and until cleared to fly by the treating team. DVT risk from immobility during flights is a genuine concern for all surgical patients and should be discussed with the surgical team.

Before leaving Turkey, obtain comprehensive written discharge notes, operative records, and any implant or product documentation. Identify a local physician or specialist who is willing to provide follow-up care before travelling, and share the Turkish records with them at the first appointment. Many Turkish hospitals have dedicated aftercare coordinators who can respond to email or telephone queries.

Standard travel insurance generally excludes complications from planned elective procedures. Medical tourism-specific insurance — available from specialist providers — covers both the procedure and post-operative complications including emergency care and repatriation. This should be purchased before travel and the policy read carefully for exclusions.

Istanbul has an extensive public transport network including metro, tram, and ferry services, and taxis and ride-hailing apps are widely available. Many clinics offer airport transfers and can arrange transport to appointments. Patients with limited mobility post-procedure should confirm accessible transport options with their clinic or hotel in advance.

The main risks are choosing a clinic where graft extraction and placement are performed by unqualified technicians rather than medical staff, and procedures conducted in facilities not registered with the Ministry of Health. Patients should confirm in writing who performs each stage of the procedure and verify that the clinic holds appropriate health tourism certification.

Hair loss depends on the specific drugs used. Some regimens cause complete hair loss, others cause thinning, and some cause none at all. Hair typically begins to fall out one to three weeks after the first treatment and regrows within two to three months of completing chemotherapy.

Many patients continue working during chemotherapy, particularly in less physically demanding roles. The ability to work depends on the regimen's intensity, the individual's response, and the nature of the job. Planning around the nadir period — when fatigue and infection risk peak — is advisable.

A varied, nutritious diet is important to maintain strength and support immune function. Nausea may limit appetite, and a dietitian can advise on strategies to maintain adequate intake. High-risk foods such as raw meat, unpasteurised dairy, and unwashed produce should be avoided during immunosuppressed periods.

Response to chemotherapy is assessed through regular imaging — CT scans, PET scans, or MRI — and blood tumour markers if applicable. These are typically performed after two to three cycles to determine whether the regimen is achieving the intended response. The treating oncologist will discuss findings and adjust the plan if necessary.

Febrile neutropenia occurs when chemotherapy reduces white blood cell counts to critically low levels and an infection develops, causing fever. Because the immune system cannot mount a normal response, this can progress rapidly to life-threatening sepsis. It requires emergency hospitalisation and prompt intravenous antibiotics.

Most side effects — including nausea, fatigue, and hair loss — are temporary and resolve after treatment ends. Some drugs carry a risk of longer-lasting or permanent effects, including peripheral neuropathy (tingling or numbness in the hands and feet), cardiac effects with certain agents, and in rare cases, secondary malignancies.

Travel is generally best avoided during the nadir period when infection risk is highest. Short trips between cycles may be feasible when blood counts have recovered, but patients should carry medical records, have access to emergency care at the destination, and avoid crowded public spaces and sick contacts.

Chemotherapy directly kills rapidly dividing cells using cytotoxic drugs. Immunotherapy works differently — it activates or modulates the patient's own immune system to recognise and attack cancer cells. Many patients now receive combinations of both approaches, and immunotherapy has dramatically improved outcomes for certain cancers including melanoma and lung cancer.